Latanoprost/timolol - Laboratoires Thea

Drug Profile

Latanoprost/timolol - Laboratoires Thea

Alternative Names: T-2347; Timolol/latanoprost - Laboratoires Thea

Latest Information Update: 13 Oct 2015

Price : $50

At a glance

  • Originator Laboratoires Thea
  • Class Amino alcohols; Antiglaucomas; Antihypertensives; Eye disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Aug 2015 Laboratoires Thea completes a phase III trial in Ocular hypertension and Glaucoma in Belgium, France, Hungary, Estonia, Spain, Germany and the United Kingdom (NCT02278614)
  • 01 Dec 2014 Phase-III clinical trials in Glaucoma in Belgium (Ophthalmic)
  • 01 Dec 2014 Phase-III clinical trials in Ocular hypertension in Belgium (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top